Isoray is excited to be supporting the upcoming Society of Gynecologic Oncology (SGO) annual meeting, which will be held March 12-15 in National Harbor, Maryland. The SGO meeting serves as a forum on women’s cancer, providing the latest clinical updates and research on a wide spectrum of gynecologic oncology topics. This meeting serves as one of the foremost opportunities each year to learn about the latest clinical and scientific contributions and to discuss brachytherapy’s potential as a novel treatment option for patients with recurrent gynecological cancer with industry leaders. Learn more about how Cesium 131 and Isoray Medical are contributing to this by visiting us at SGO booth #525.
Cesium-131 brachytherapy as a novel treatment option for patients with recurrent gynecological cancer
The position of many gynecologic tumors to sensitive surrounding organs requires precise delivery of radiation to limit toxicity to the nearby organs. For initial treatment this should not impact patient therapeutic options, however in the case of recurrence, there are limited options for additional radiation. This often results in radical surgeries or palliative therapies as the only treatment options for recurrent disease. As an alternative, some clinicians are considering permanent interstitial brachytherapy for gynecologic cancer as opposed to more radical approaches.
During SGO, Cesium pioneers Dr. Jonathan Feddock and Dr. Marcus Randall will be presenting breakthrough data describing a permanent template-guided interstitial technique using Cesium-131 for recurrent gynecologic cancers, performed as a low dose radiation (LDR) outpatient procedure- providing promise for patients battling recurrent gynecological cancers.
The study was conducted by Drs. Feddock and Randall with Prakash Aryal, Cole Steber, Jason Edwards and Dennis Cheek using permanent template-guided brachytherapy technique with Cesium-131. The study concludes that, compared to current template-guided techniques, use of Cesium-131 implants avoids prolonged bed rest and hospitalization, lowers treatment costs, and enables a higher cumulative dose.
“These women were facing very radical surgery to address their recurrent cancers and it turned out that Cesium-131 therapy offered a much better solution for them.” – Dr. Jonathan Feddock, MD, Assistant Professor of Radiation Medicine, University of Kentucky College of Medicine.
Read a synopsis of the abstract including purpose, methods, results and conclusion here.
We are particularly eager to attend the Education Forum XI – Targeted Therapy session on Tuesday at 4:30.
You can access the full agenda here.
If you would like to learn more about brachytherapy as a novel treatment option for women’s cancer or if you just want to talk about the latest innovation in gynecologic oncology prevention and patient care, we want to connect with you! Contact Bill Gallien at wgallien@isoray.flywheelstaging.com or directly at (330) 388-8106 to arrange a meeting at SGO 2017!
